W2O Sentient announced the appointment of respected industry leaders Dominic Viola as Managing Director, Client Services, and Michael Spitz as Practice Leader, Strategy.
Discovery Worldwide announced the appointment of Stephanie Franke as VP, Creative Director. Franke reports directly to TJ Cimfel, Group VP Creative Director.
Takeda Pharmaceutical announced a collaboration to help transform novel Stanford University research into next-generation treatments for diseases.
CEL-SCI received a letter from the U.S. FDA stating that the clinical hold that had been imposed on the company’s Phase 3 cancer study with Multikine was removed.
Stimwave LLC received FDA 510(k) clearance for the first wireless, micro-technology neuromodulation device that can enable ongoing full-body MRI scans under certain scanning conditions for the relief of chronic peripheral nerve pain.
The FDA cleared Optovue’s epithelial thickness mapping software (epi-mapping) for quantitative measurements of the epithelial and stromal layers of the cornea.
Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration approved QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and older.
Ex-Edelman Leader to Direct Growth and Evolution of One of W2O’s Largest Firms Annalise Coady to Focus on Building W2O’s EMEA Presence SAN FRANCISCO, August 3, 2017 — […]
Kite Pharma Inc. highlighted the publication of the first large-scale multi-institutional analysis of outcomes of patients with refractory aggressive non-Hodgkin lymphoma (NHL) in the latest electronic edition of BLOOD.
In line with Ocular Therapeutix Inc.’s strategic plan and growth objectives announced in June 2017, Antony Mattessich assumed the role of CEO of the biopharmaceutical company.
